Anjay Rastogi - Concepedia

Author

Anjay Rastogi

University of California, Los Angeles ORCID

Also Known As

A Rastogi, A. Rastogi, A., Rastogi, Anjay Rastogi, Anusha Rastogi, Anushri Rastogi, M. Ketteler, Mahboob Rahman, Rastogi, A., Rastogi, Anjay

192

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Wake Forest University University of Utah University of Chicago Stanford University

About

Anjay Rastogi is an author at University of California, Los Angeles specializing in medicine, nephrology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	2.9K
2	Public Health	3	3	54
3	Health Sciences	2	2	48
4	Nursing	1	1	19
5	Biochemistry	1	1	189

Anjay Rastogi

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis Bevra H. Hahn, Maureen McMahon, Alan Wilkinson, Arthritis Care & Research Glomerular DiseaseRheumatology GuidelinesRenal PathologyPulse GlucocorticoidsUnited States	2012	1.5K
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia Louis Holdstock, Amy M. Meadowcroft, Rayma Maier, Journal of the American Society of Nephrology Hemodialysis StudyDialysis TherapyPharmacotherapyRedox BiologyOxidative Stress	2015	189
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients Jürgen Floege, Adrian Covic, Markus Ketteler, Kidney International HemodialysisUrologyRenal FunctionSevelamer CarbonateKidney Failure	2014	184
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia Steven Fishbane, Martin L. Ford, Masafumi Fukagawa, Journal of the American Society of Nephrology	2019	142
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients Jürgen Floege, Adrian Covic, Markus Ketteler, Nephrology Dialysis Transplantation	2015	140
The Difference Between Cystatin C– and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) Onur Potok, Joachim H. Ix, Michael G. Shlipak, American Journal of Kidney Diseases Renal FunctionHealth PolicyMedicineAdverse OutcomesCohort Analysis	2020	120
Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial Bharathi Upadhya, Michael V. Rocco, Cora E. Lewis, Circulation Heart Failure	2017	114
Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease Srinivasan Beddhu, Michael V. Rocco, Robert D. Toto, Annals of Internal Medicine	2017	107
Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients Joshua J. Zaritsky, Brian Young, Barbara Gales, Clinical Journal of the American Society of Nephrology	2010	105

Page 1